Actimo Labs Pty Ltd (ACN 682 666 495)
Enhancing antibody safety through AI
Actimo Labs delivers CRO 2.0, the new age of AI driven pre-clinical screening tests.
Site specific modelling of your antibody so you can innovate with confidence.
Epitope Mapping
We map epitopes on the antigen to help us identify the paratope on different types of mAbs. Our comprehensive antibody-antigen affinity reports are effective and quick, allowing you to gain insights into your mAb early in its development and strengthen your IP.
Off-target Prediction
By predicting the off-target sites early in the development process, we assist our clients in reducing the risk of adverse side effects and improving drug safety profiles.
Work closely with our team to unlock sharp insights and iterate quickly. Skip the wait of traditional tissue cross-reactivity screens and reach out to us today.
Our Incubators & Partners
Frequently Asked Questions
Have questions about how we can accelerate your antibody's preclinical development? Explore our FAQs below for quick answers.
How does Actimodel work?
By using your sequence and structure data, we will annotate your antibody, map the binding sites on the antibody and the antigen, conduct similarity tests, and rank the affinity of binding sites in our comprehensive off-target screen reports.
When will Actimodel launch?
Our Epitope Mapping services will be available in late March 2025.
Full in-silico Off-Target Screens will launch in Q4 2025. Join our newsletter to stay up to date with product and feature releases.
How can I engage with your services now?
We are currently partnered with the Brain Cancer Immunotherapy Lab at the Walter Eliza Hall Institute to refine our technology.
If you are a clinical researcher or computational biologist who could benefit from our services, please reach out to us to discuss how we can help your antibody get to market quicker.
Still have a question?
Speak to a member of our team below.